ArticleDiscover oncology2025
Mapping the landscape of metabolic reprogramming research in lung cancer: a bibliometric and visualized analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quetiapine inhibits the oxidative phosphorylation in head and neck squamous cell carcinoma through suppressing NAT10-mediated ac4C modification.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLung cancer is the leading cause of cancer-related deaths worldwide, with a poor prognosis despite advancements in diagnosis and treatment. Metabolic reprogramming, a key feature of cancer, allows tumor cells to survive and grow under harsh conditions, making it a crucial area of study. This study provides a comprehensive analysis of global trends, influential studies, and key developments in this field.
methodsWe conducted a bibliometric analysis using the Web of Science Core Collection (WoSCC) database from 2004 to 2024. Publications related to metabolic reprogramming and lung cancer were retrieved and analyzed using VOSviewer and CiteSpace to examine publication trends, research collaborations, keyword co-occurrence, and citation networks.
resultsA total of 1078 publications were analyzed, with research output increasing significantly after 2015. China and the United States were the leading contributors, engaging in extensive international collaborations. Pioneering studies by researchers such as Ralph J. DeBerardinis and Otto Warburg underscored the importance of altered metabolism in lung cancer. Key emerging topics included the role of cancer stem cells, changes in tumor metabolism, and new treatment approaches targeting metabolic pathways. The integration of laboratory research with clinical applications, including novel drugs and immunotherapies, demonstrated promising directions for future treatments.
conclusionsThis bibliometric analysis maps the research landscape of metabolic reprogramming in lung cancer, identifying influential contributors and emerging research themes. Future studies should explore advanced technologies like single-cell analysis and investigate how metabolic changes are regulated at the molecular level. A deeper understanding of these processes could lead to innovative treatment strategies and better patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.